The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.

LOS ANGELES, Dec. 13 (Xinhua) -- An injectable HIV drug with novel mechanism was named on Thursday by the influential U.S. journal "Science" as Breakthrough of the Year. The drug, named lenacapavir, ...

Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

The next year brought the breakthrough that still defines HIV treatment today: highly active antiretroviral therapy (HAART). HAART uses three or more drugs that work in at least two different ways.

Science, a global scientific journal, has selected lenacapavir (lenacapavir), a groundbreaking HIV infection treatment, and related studies for the '2024 Innovation of the Year'. Renacapavir, an ...

A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...

Lenacapavir, an injectable drug for HIV prevention, is praised as a potential game-changer and offers hope for those who find daily oral medications challenging. The drug requires administration ...